AR057525A1 - Compuestos inhibidores selectivos de gsk3 y un proceso para su preparacion - Google Patents
Compuestos inhibidores selectivos de gsk3 y un proceso para su preparacionInfo
- Publication number
- AR057525A1 AR057525A1 ARP060104309A ARP060104309A AR057525A1 AR 057525 A1 AR057525 A1 AR 057525A1 AR P060104309 A ARP060104309 A AR P060104309A AR P060104309 A ARP060104309 A AR P060104309A AR 057525 A1 AR057525 A1 AR 057525A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- haloalkyl
- optionally substituted
- ora
- halo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0502173 | 2005-10-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR057525A1 true AR057525A1 (es) | 2007-12-05 |
Family
ID=37906402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060104309A AR057525A1 (es) | 2005-10-03 | 2006-09-29 | Compuestos inhibidores selectivos de gsk3 y un proceso para su preparacion |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20080255106A1 (enExample) |
| EP (1) | EP1934217A4 (enExample) |
| JP (1) | JP2009510162A (enExample) |
| KR (1) | KR20080057334A (enExample) |
| CN (1) | CN101321754A (enExample) |
| AR (1) | AR057525A1 (enExample) |
| AU (1) | AU2006297889A1 (enExample) |
| BR (1) | BRPI0616663A2 (enExample) |
| CA (1) | CA2624869A1 (enExample) |
| IL (1) | IL189945A0 (enExample) |
| NO (1) | NO20082054L (enExample) |
| SA (1) | SA06270365B1 (enExample) |
| TW (1) | TW200800984A (enExample) |
| UY (1) | UY29823A1 (enExample) |
| WO (1) | WO2007040439A1 (enExample) |
| ZA (1) | ZA200802637B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY29825A1 (es) * | 2005-10-03 | 2007-05-31 | Astrazeneca Ab | Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones |
| JP2009523845A (ja) * | 2006-01-23 | 2009-06-25 | クリスタルゲノミクス インコーポレーテッド | たんぱく質キナーゼの活性を阻害するイミダゾピリジン誘導体、これの製造方法およびこれを含む薬学組成物 |
| JP2010523490A (ja) * | 2007-03-30 | 2010-07-15 | アストラゼネカ・アクチエボラーグ | 新規イミダゾ［４，５−ｂ］ピリジン−７−カルボキサミド７０４ |
| CN102127070A (zh) * | 2010-01-15 | 2011-07-20 | 山东轩竹医药科技有限公司 | 吡啶并环衍生物 |
| KR101889993B1 (ko) * | 2010-09-10 | 2018-08-20 | 시오노기세야쿠 가부시키가이샤 | Ａｍｐｋ 활성화 작용을 갖는 헤테로환 축합 이미다졸 유도체 |
| JP2017524739A (ja) | 2014-07-17 | 2017-08-31 | アンセルムＩｎｓｅｒｍ | 神経筋接合部関連疾患の処置方法 |
| WO2016207366A1 (en) | 2015-06-26 | 2016-12-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of viral infections |
| GB201519573D0 (en) | 2015-11-05 | 2015-12-23 | King S College London | Combination |
| CN107151235B (zh) * | 2016-03-04 | 2019-12-13 | 上海市计划生育科学研究所 | 噻二唑烷二酮基gsk3抑制剂在调节精子运动能力中的用途 |
| ES2896938T3 (es) * | 2016-11-28 | 2022-02-28 | Bristol Myers Squibb Co | Inhibidores de GSK-3 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999007703A1 (en) * | 1997-08-05 | 1999-02-18 | Pfizer Products Inc. | 4-AMINOPYRROLE(3,2-d) PYRIMIDINES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS |
| US6187777B1 (en) * | 1998-02-06 | 2001-02-13 | Amgen Inc. | Compounds and methods which modulate feeding behavior and related diseases |
| KR20040084896A (ko) * | 2002-02-06 | 2004-10-06 | 버텍스 파마슈티칼스 인코포레이티드 | Ｇｓｋ-3의 억제제로서 유용한 헤테로아릴 화합물 |
| BR0308785A (pt) * | 2002-03-27 | 2005-01-11 | Altana Pharma Ag | Derivados de alcoxipiridina |
| SE0202462D0 (sv) * | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel use |
| WO2004065370A1 (en) * | 2003-01-23 | 2004-08-05 | Crystalgenomics, Inc. | Glycogen synthase kinase 3beta inhibitor, composition and process for the preparation thereof |
| NZ546437A (en) * | 2003-10-01 | 2009-09-25 | Altana Pharma Ag | Imidazopyridine-derivatives as inducible NO-synthase inhibitors |
| ATE399168T1 (de) * | 2003-10-01 | 2008-07-15 | Nycomed Gmbh | Imidazopyridin-derivate und ihre verwendung als induzierbare no-synthase inhibitoren |
| UY29825A1 (es) * | 2005-10-03 | 2007-05-31 | Astrazeneca Ab | Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones |
| JP2009523845A (ja) * | 2006-01-23 | 2009-06-25 | クリスタルゲノミクス インコーポレーテッド | たんぱく質キナーゼの活性を阻害するイミダゾピリジン誘導体、これの製造方法およびこれを含む薬学組成物 |
-
2006
- 2006-09-29 AR ARP060104309A patent/AR057525A1/es not_active Application Discontinuation
- 2006-09-29 UY UY29823A patent/UY29823A1/es not_active Application Discontinuation
- 2006-10-02 EP EP06799715A patent/EP1934217A4/en not_active Withdrawn
- 2006-10-02 BR BRPI0616663-6A patent/BRPI0616663A2/pt not_active IP Right Cessation
- 2006-10-02 KR KR1020087010754A patent/KR20080057334A/ko not_active Withdrawn
- 2006-10-02 CA CA002624869A patent/CA2624869A1/en not_active Abandoned
- 2006-10-02 WO PCT/SE2006/001115 patent/WO2007040439A1/en not_active Ceased
- 2006-10-02 CN CNA2006800453255A patent/CN101321754A/zh active Pending
- 2006-10-02 US US12/088,897 patent/US20080255106A1/en not_active Abandoned
- 2006-10-02 JP JP2008534485A patent/JP2009510162A/ja active Pending
- 2006-10-02 AU AU2006297889A patent/AU2006297889A1/en not_active Abandoned
- 2006-10-03 SA SA06270365A patent/SA06270365B1/ar unknown
- 2006-10-03 TW TW095136782A patent/TW200800984A/zh unknown
-
2008
- 2008-03-04 IL IL189945A patent/IL189945A0/en unknown
- 2008-03-25 ZA ZA200802637A patent/ZA200802637B/xx unknown
- 2008-04-30 NO NO20082054A patent/NO20082054L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL189945A0 (en) | 2008-08-07 |
| ZA200802637B (en) | 2008-12-31 |
| US20080255106A1 (en) | 2008-10-16 |
| CN101321754A (zh) | 2008-12-10 |
| AU2006297889A1 (en) | 2007-04-12 |
| UY29823A1 (es) | 2007-05-31 |
| WO2007040439A1 (en) | 2007-04-12 |
| TW200800984A (en) | 2008-01-01 |
| KR20080057334A (ko) | 2008-06-24 |
| NO20082054L (no) | 2008-06-02 |
| EP1934217A4 (en) | 2010-08-04 |
| SA06270365B1 (ar) | 2009-12-22 |
| BRPI0616663A2 (pt) | 2011-06-28 |
| CA2624869A1 (en) | 2007-04-12 |
| JP2009510162A (ja) | 2009-03-12 |
| EP1934217A1 (en) | 2008-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR061371A1 (es) | Amino - imidazolonas y su uso como medicamento para la enfermedad de alzheimer y otras enfermedades neurodegenerativas. | |
| AR055669A1 (es) | Derivados de 3h - imidazo[4, 5 -b]piridina como inhibidores selectivos de gsk3, metodos e internediarios para su preparacion, composiciones farmaceuticas que los contienen y su uso para la elaboracion de un medicamento para el tratamiento de enfermedades neurodegenerativas y mentales. | |
| AR119698A2 (es) | Compuesto amida n-urea sustituida derivado de aminoácido | |
| AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
| AR075139A1 (es) | Compuestos biciclicos para la reduccion de la produccion de beta-amiloide | |
| PE20250674A1 (es) | Compuestos heterociclicos como inmunomoduladores | |
| AR050188A1 (es) | Compuestos heterociclicos condensados utiles en terapia como inhibidores de quinasas p38 y composiciones farmaceuticas que los contienen | |
| AR058073A1 (es) | Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos | |
| AR062677A1 (es) | Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR072227A1 (es) | Derivados de triazinona sustituidos | |
| AR070828A1 (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| AR066972A1 (es) | Derivados azapeptidicos | |
| AR058885A1 (es) | Compuestos de piperidina 3,5-sustituidos | |
| AR063988A1 (es) | Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| AR058287A1 (es) | Derivados de isoquinolina y composicion farmaceutica | |
| AR066460A2 (es) | Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos | |
| AR040352A1 (es) | Derivados de indolinfenilsulfonamida | |
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| AR038686A1 (es) | Formulaciones de derivados de androstano y agonistas del adrenoreceptor beta 2 antiinflamatorios | |
| AR055878A1 (es) | Derivados de ciclopropanocarboxamida | |
| AR036604A1 (es) | Derivados de 4-pirimidona 3-sustituida | |
| AR045113A1 (es) | Derivados sustituidos del dioxido de tiazolbenzoisotiazol, procedimiento para su preparacion y su uso | |
| HRP20050543A2 (en) | Substituted indolepyridinium as anti-infective compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |